Healthcare Mar 15, 2022 10:01 AM (GMT+8) · EqualOcean
Recently, Beijing Yiyao Technology Co., Ltd. announced that it had completed ten million yuan Angel + round financing from Xiantong capital. It is reported that this round of funds will be used for the development of desktop version of lingsu drug development system, accelerate the rapid promotion of the company's research pipeline in the direction of prolonging life and metabolic diseases, improve the construction of cloud computing platform, innovative R & D laboratory, recruitment team, patent layout, etc. Yiyao technology was founded in 2018. Previously, it developed the world's leading efficacy prediction system based on deep learning and gene fingerprinting (dleps, dexamethasone system). The pheromone system can accurately predict the changes of gene expression profile after small molecule treatment of cells or animals, and expand the applicable molecular space to more than "100 million". The psionic system is especially suitable for areas where traditional methods are not good at, and has been verified in many important disease directions. At present, Yiyao technology has publicly released the progress made in weight loss, uric acid reduction, nonalcoholic steatohepatitis (NASH) and other diseases.

This text is a result of machine translation.